Contact
![](/sites/default/files/styles/medium_220px_width/public/2020-11/nahiaprueba_0.jpg?itok=lGhKXjfl)
It its latest issue, Correo Farmacéutico, a weekly paper published by the Unidad Editorial group, gives special mention to the Diomed project, headed by Antonio Zorzano, coordinator of the Molecular Medicine Programme at IRB Barcelona. The highlight is part of an article on the diabetes "epidemic" and on the international search for drugs in order to tackle the current lack of treatment for this disease.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).